Quick Takeaways
- PHGE - BiomX Inc. has 25 insiders with reported activity on this page.
- Net insider value flow over the last year: -$8,250,000.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 25 Insiders of BiomX Inc.
- Symbol
- PHGE on NYSE
- Location
- Dover, DE
What Changed
- Buy value: ; sell value: $8,250,000.
- Net share flow: -1,650,000.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$8,250,000.
Buys
$0
Shares: 0
Insiders: 0
Sells
$8,250,000
Shares: 1,650,000
Insiders: 1
Net
-$8,250,000
Shares: -1,650,000
Insiders: -1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 1,650,000 | $0 | $8,250,000 | -$8,250,000 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
BiomX Inc. executives and other stock owners filed with the SEC include:
Top shareholders of BiomX Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| OrbiMed Israel BioFund GP Limited Partnership |
3/4/5
13D/G
|
10%+ Owner · ORBIMED ISRAEL GP LTD. |
1%
from 13D/G
|
13,777,980
mixed-class rows
|
$5,250,517 | — | 15 May 2024 | |
| James E. Flynn |
3/4/5
13D/G
|
Director, *Director by Deputization · Deerfield Management Company, L.P. |
10%
from 13D/G
|
5,831,350
mixed-class rows
|
$2,321,016 | — | 21 Apr 2025 | |
| Cystic Fibrosis Foundation |
3/4/5
13D/G
|
10%+ Owner |
10%
from 13D/G
|
11,131,426
mixed-class rows
|
$1,663,688 | — | 26 Feb 2025 | |
| Centaurus Investments Ltd |
13D/G
|
Rodney Hodges |
7.6%
|
1,970,403
|
$1,182,242 | $0 | 21 Apr 2025 | |
| Chidozie Ugwumba |
3/4/5
|
Exit Form 4 - former 10% owner |
—
class O/S missing
|
2,997,025
|
$1,018,989 | — | 17 Oct 2022 | |
| Nantahala Capital Management, LLC |
13D/G
13F
|
Company |
10%
|
156,696
|
$355,700 | $0 | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
8.4%
|
131,270
|
$245,471 | — | 31 Dec 2025 | |
| Reuven Yeganeh |
13D/G
|
— |
20%
|
381,422
|
$99,170 | $0 | 26 Dec 2025 | |
| Jonathan Eitan Solomon |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
507,248
mixed-class rows
|
$72,246 | — | 14 Apr 2025 | |
| Merav Bassan |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
174,597
mixed-class rows
|
$45,370 | — | 14 Apr 2025 | |
| Marina Wolfson |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
163,545
mixed-class rows
|
$39,070 | — | 14 Apr 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
1.2%
|
19,473
|
$36,414 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.2%
|
18,707
|
$34,982 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.9%
|
14,135
|
$26,432 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13D/G
|
— |
2.5%
|
38,176
|
$9,926 | -$592,254 | 31 Dec 2025 | |
| Orin Hirschman |
13D/G
|
— |
0.1%
|
38,175
|
$9,926 | -$397,480 | 31 Dec 2025 | |
| Assaf Oron |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
263,304
mixed-class rows
|
$9,836 | — | 16 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.15%
|
2,279
|
$4,261 | — | 31 Dec 2025 | |
| Paul J. Sekhri |
3/4/5
|
Director |
—
mixed-class rows
|
21,875
mixed-class rows
|
$4,250 | — | 28 Jul 2021 | |
| BARCLAYS PLC |
13F
|
Company |
0.08%
|
1,316
|
$2,461 | — | 31 Dec 2025 | |
| Clear Street Group Inc. |
13F
|
Company |
0.01%
|
120
|
$224 | — | 31 Dec 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
20
|
$37 | — | 31 Dec 2025 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$2 | — | 31 Dec 2025 | |
| T3 Defense Inc. |
13D/G
|
Menachem Shalom |
20%
|
1,600,000
|
— | $0 | 10 Apr 2026 | |
| Dambach Michael E. |
3/4/5
|
Director |
—
class O/S missing
|
41,000
|
— | — | 21 Aug 2023 | |
| Lynne Marie Sullivan |
3/4/5
|
Director |
—
class O/S missing
|
41,000
|
— | — | 01 Mar 2023 | |
| Marks Jason M. |
3/4/5
|
Director |
—
class O/S missing
|
41,000
|
— | — | 21 Aug 2023 | |
| Russell Greig |
3/4/5
|
Director |
—
class O/S missing
|
35,200
|
— | — | 14 Apr 2025 | |
| Gbolahan Amusa |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 29 Mar 2022 | |
| Jonas Grossman |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 29 Mar 2022 | |
| Alan Charles Moses |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Eddie Williams |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Gregory Louis Merril |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Jesse Goodman |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Jonathan S. Leff |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Susan Blum |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 |
Recent Insider Transactions by Companies or Individuals for BiomX Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Reuven Yeganeh | PHGE | Common Stock, $0.0001 par value per share | Sale | -100% | $2,650,000 | $5.00 | -530,000 | 0 | 17 Mar 2026 | Pyu Pyu Capital LLC |
| Reuven Yeganeh | PHGE | Common Stock, $0.0001 par value per share | Conversion of derivative security | 530,000 | 530,000 | 17 Mar 2026 | Pyu Pyu Capital LLC | |||
| Reuven Yeganeh | PHGE | Series Y Convertible Preferred Stock | Conversion of derivative security | -100% | -1,060 | 0 | 17 Mar 2026 | Pyu Pyu Capital LLC | ||
| Reuven Yeganeh | PHGE | Common Stock, $0.0001 par value per share | Sale | -100% | $2,250,000 | $5.00 | -450,000 | 0 | 16 Mar 2026 | Pyu Pyu Capital LLC |
| Reuven Yeganeh | PHGE | Common Stock, $0.0001 par value per share | Conversion of derivative security | 450,000 | 450,000 | 16 Mar 2026 | Pyu Pyu Capital LLC | |||
| Reuven Yeganeh | PHGE | Common Stock Purchase Warrants | Sale | -100% | -5,000,000 | 0 | 16 Mar 2026 | Pyu Pyu Capital LLC | ||
| Reuven Yeganeh | PHGE | Series Y Convertible Preferred Stock | Conversion of derivative security | -45.9% | -900 | 1,060 | 16 Mar 2026 | Pyu Pyu Capital LLC | ||
| Reuven Yeganeh | PHGE | Common Stock, $0.0001 par value per share | Sale | -100% | $1,850,000 | $5.00 | -370,000 | 0 | 13 Mar 2026 | Pyu Pyu Capital LLC |
| Reuven Yeganeh | PHGE | Common Stock, $0.0001 par value per share | Conversion of derivative security | 370,000 | 370,000 | 13 Mar 2026 | Pyu Pyu Capital LLC | |||
| Reuven Yeganeh | PHGE | Series Y Convertible Preferred Stock | Conversion of derivative security | -27.4% | -740 | 1,960 | 13 Mar 2026 | Pyu Pyu Capital LLC | ||
| Reuven Yeganeh | PHGE | Common Stock, $0.0001 par value per share | Sale | -100% | $1,500,000 | $5.00 | -300,000 | 0 | 12 Mar 2026 | Pyu Pyu Capital LLC |
| Reuven Yeganeh | PHGE | Series Y Convertible Preferred Stock | Conversion of derivative security | -18.2% | -600 | 2,700 | 12 Mar 2026 | Pyu Pyu Capital LLC | ||
| Reuven Yeganeh | PHGE | Common Stock, $0.0001 par value per share | Conversion of derivative security | 300,000 | 30,000 | 11 Mar 2026 | Pyu Pyu Capital LLC |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.